Showing results (41-50 of 58) with videos related to
Sort By:
Pageof 6
Leukemia|June 14, 2023
Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantationEnrique M Ocio, Aurore Perrot, Pierre Bories, et al.Eclinicalmedicine|July 3, 2023
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencingStefania Oliva, Elisa Genuardi, Laura Paris, et al.Blood|January 19, 2017
Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myelomaMariateresa Fulciniti, Joaquin Martinez-Lopez, William Senapedis, et al.Cancer|September 21, 2011
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patientsAlessandro Gozzetti, Alfonso Cerase, Flavia Lotti, et al.Blood|December 4, 2023
Predictors of unsustained measurable residual disease negativity in patients with multiple myelomaMattia D'Agostino, Giuseppe Bertuglia, Delia Rota-Scalabrini, et al.The Lancet. Oncology|November 25, 2015
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trialFrancesca Gay, Stefania Oliva, Maria Teresa Petrucci, et al.Blood|December 28, 2020
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data setAjai Chari, Mehmet Kemal Samur, Joaquin Martinez-Lopez, et al.Blood Cancer Journal|June 4, 2021
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trialStefania Oliva, Davine Hofste Op Bruinink, Lucie Rihova, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple MyelomaLuca Bertamini, Stefania Oliva, Delia Rota-Scalabrini, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2025
Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized TrialsQian Shi, Bruno Paiva, Levi D Pederson, et al.Pageof 6